Anemia Before SBRT Linked to Poor Survival in Stage I NSCLC

Share this content:
Pretreatment anemia may be predictive of aggressive disease with poor survival and non-local disease progression in non-small cell lung cancer.
Pretreatment anemia may be predictive of aggressive disease with poor survival and non-local disease progression in non-small cell lung cancer.

Pretreatment anemia may be predictive of aggressive disease with poor survival and non-local disease progression among patients with early-stage non-small cell lung cancer (NSCLC) undergoing stereotactic body radiation therapy (SBRT), according to a study published in the Journal of Thoracic Oncology.1

Researchers analyzed data from 147 patients with stage I NSCLC who received SBRT. Pretreatment hemoglobin levels were evaluated to determine whether there is an association with local, regional, and distant control, disease-free survival, and overall survival. Another objective was to determine the optimal pretreatment hemoglobin level for predicting poorer outcomes.

Results showed that at a median follow-up of 28.9 months, the 3-year local, regional, and distant control rates were 95%, 87%, and 89%, respectively. The 3-year overall survival rate was 75%, while the 3-year disease-free survival rate was 83%.

RELATED: In Extensive Stage SCLC, Sonidegib With Etoposide, Cisplatin May Be Effective

After adjusting for age, T-stage, and radiation dose, researchers found that a lower pretreatment hemoglobin level was associated with poor regional control, poor disease-free survival, and poor overall survival (P = .02, P = .03, P = .05, respectively). Pretreatment anemia did not, however, predict for local disease control.

The study demonstrated that pretreatment hemoglobin levels less than 12.2 g/dL were optimal for predicting poor regional control and disease-free survival. The 3-year disease-free survival for patients with a hemoglobin level less than 12.2 g/dL was 70% compared with 94% among patients with a hemoglobin level of 12.2 g/dL or higher (P = .008).

Reference

  1. Shaverdian N, Veruttipong D, Wang J, Kupelian P, Steinberg M, Lee P. Pretreatment anemia portends poor survival and non-local disease progression in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy [published online ahead of print May 24, 2016]. J Thorac Oncol. doi: 10.1016/j.jtho.2016.04.030.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs